TransCode Therapeutics spent the past year converting a cash-starved RNA shop into a multi-platform oncology company by handing most of the residual claim to a Hong Kong-listed life-sciences parent. The Polynoma purchase brought a late-stage melanoma vaccine and a cash infusion, and the Unleash license added a preclinical oncolytic-virus stack, all paid mostly in convertible preferred rather than cash. Common holders now sit under that preferred stack, a going-concern warning, and a Yorkville equity line that prices stock at a discount to a short-window volume-weighted average. The investment debate is whether circulating-tumor-DNA clearance in colorectal residual disease can outrun the dilution machine before year-end cash runs out.
The mid-year print is the first full look at the post-deal cost base. Research spending rose as the lead RNA candidate moved from dose escalation into an expansion study. A one-time in-process charge of $10 million for the Unleash license dominated the first-half loss. Cash of $8 million at the mid-year close sits well below the year-end starting point even after the CK Life Sciences subscription. Management states existing cash plus a mid-summer convertible note funds operations only to approximately year-end. The balance sheet still carries a large in-process research asset from Polynoma that is not cash and does not fund the next trial.
The June safety update on the lead candidate is the only clinical evidence the market can price today. Sixteen patients received the drug across four dose levels with no dose-limiting toxicities. Nine of fourteen evaluable patients held stable disease for half a year. That is a cytostatic signal in late-line metastatic disease, not a registrational package, and the expansion study still has to enroll. Can circulating-tumor-DNA clearance in the colorectal residual-disease cohort arrive before the Yorkville line and the next equity raise reprice the residual claim?